nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—CYP2E1—Methimazole—Graves' disease	0.201	0.252	CbGbCtD
Imipramine—CYP2B6—Methimazole—Graves' disease	0.199	0.248	CbGbCtD
Imipramine—CYP2C19—Methimazole—Graves' disease	0.126	0.158	CbGbCtD
Imipramine—CYP1A2—Methimazole—Graves' disease	0.116	0.146	CbGbCtD
Imipramine—CYP2D6—Methimazole—Graves' disease	0.0959	0.12	CbGbCtD
Imipramine—CYP3A4—Methimazole—Graves' disease	0.061	0.0763	CbGbCtD
Imipramine—Drug fever—Methimazole—Graves' disease	0.0237	0.126	CcSEcCtD
Imipramine—Epigastric distress—Methimazole—Graves' disease	0.0204	0.108	CcSEcCtD
Imipramine—Drug fever—Propylthiouracil—Graves' disease	0.0201	0.107	CcSEcCtD
Imipramine—Epigastric distress—Propylthiouracil—Graves' disease	0.0173	0.092	CcSEcCtD
Imipramine—Drowsiness—Methimazole—Graves' disease	0.00442	0.0235	CcSEcCtD
Imipramine—Neuropathy peripheral—Methimazole—Graves' disease	0.00433	0.023	CcSEcCtD
Imipramine—Jaundice—Methimazole—Graves' disease	0.00431	0.0229	CcSEcCtD
Imipramine—Agranulocytosis—Methimazole—Graves' disease	0.00412	0.0219	CcSEcCtD
Imipramine—Hepatitis—Methimazole—Graves' disease	0.00397	0.0211	CcSEcCtD
Imipramine—Drowsiness—Propylthiouracil—Graves' disease	0.00376	0.02	CcSEcCtD
Imipramine—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00368	0.0196	CcSEcCtD
Imipramine—Jaundice—Propylthiouracil—Graves' disease	0.00366	0.0195	CcSEcCtD
Imipramine—Agranulocytosis—Propylthiouracil—Graves' disease	0.00351	0.0186	CcSEcCtD
Imipramine—Alopecia—Methimazole—Graves' disease	0.0035	0.0186	CcSEcCtD
Imipramine—Hepatitis—Propylthiouracil—Graves' disease	0.00337	0.0179	CcSEcCtD
Imipramine—Leukopenia—Methimazole—Graves' disease	0.00309	0.0164	CcSEcCtD
Imipramine—Alopecia—Propylthiouracil—Graves' disease	0.00298	0.0158	CcSEcCtD
Imipramine—Dysgeusia—Propylthiouracil—Graves' disease	0.00287	0.0153	CcSEcCtD
Imipramine—Oedema—Methimazole—Graves' disease	0.00282	0.015	CcSEcCtD
Imipramine—Thrombocytopenia—Methimazole—Graves' disease	0.00276	0.0147	CcSEcCtD
Imipramine—Leukopenia—Propylthiouracil—Graves' disease	0.00263	0.014	CcSEcCtD
Imipramine—Paraesthesia—Methimazole—Graves' disease	0.00253	0.0134	CcSEcCtD
Imipramine—Somnolence—Methimazole—Graves' disease	0.0025	0.0133	CcSEcCtD
Imipramine—Dyspepsia—Methimazole—Graves' disease	0.00248	0.0132	CcSEcCtD
Imipramine—Oedema—Propylthiouracil—Graves' disease	0.0024	0.0127	CcSEcCtD
Imipramine—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00235	0.0125	CcSEcCtD
Imipramine—Urticaria—Methimazole—Graves' disease	0.00224	0.0119	CcSEcCtD
Imipramine—Body temperature increased—Methimazole—Graves' disease	0.00223	0.0118	CcSEcCtD
Imipramine—Paraesthesia—Propylthiouracil—Graves' disease	0.00215	0.0114	CcSEcCtD
Imipramine—Somnolence—Propylthiouracil—Graves' disease	0.00213	0.0113	CcSEcCtD
Imipramine—Dyspepsia—Propylthiouracil—Graves' disease	0.00211	0.0112	CcSEcCtD
Imipramine—Pruritus—Methimazole—Graves' disease	0.00199	0.0106	CcSEcCtD
Imipramine—Urticaria—Propylthiouracil—Graves' disease	0.0019	0.0101	CcSEcCtD
Imipramine—Body temperature increased—Propylthiouracil—Graves' disease	0.00189	0.0101	CcSEcCtD
Imipramine—Vomiting—Methimazole—Graves' disease	0.00179	0.00952	CcSEcCtD
Imipramine—Rash—Methimazole—Graves' disease	0.00178	0.00944	CcSEcCtD
Imipramine—Dermatitis—Methimazole—Graves' disease	0.00177	0.00943	CcSEcCtD
Imipramine—Headache—Methimazole—Graves' disease	0.00177	0.00938	CcSEcCtD
Imipramine—Pruritus—Propylthiouracil—Graves' disease	0.0017	0.00901	CcSEcCtD
Imipramine—Nausea—Methimazole—Graves' disease	0.00167	0.0089	CcSEcCtD
Imipramine—Vomiting—Propylthiouracil—Graves' disease	0.00152	0.0081	CcSEcCtD
Imipramine—Rash—Propylthiouracil—Graves' disease	0.00151	0.00803	CcSEcCtD
Imipramine—Dermatitis—Propylthiouracil—Graves' disease	0.00151	0.00802	CcSEcCtD
Imipramine—Headache—Propylthiouracil—Graves' disease	0.0015	0.00798	CcSEcCtD
Imipramine—Nausea—Propylthiouracil—Graves' disease	0.00142	0.00756	CcSEcCtD
Imipramine—KCND2—pituitary gland—Graves' disease	0.000557	0.0789	CbGeAlD
Imipramine—KCND2—adipose tissue—Graves' disease	0.000554	0.0785	CbGeAlD
Imipramine—CHRM5—eye—Graves' disease	0.000487	0.069	CbGeAlD
Imipramine—KCND3—adipose tissue—Graves' disease	0.000483	0.0685	CbGeAlD
Imipramine—KCND3—thyroid gland—Graves' disease	0.000418	0.0593	CbGeAlD
Imipramine—SLC22A3—connective tissue—Graves' disease	0.000302	0.0428	CbGeAlD
Imipramine—SLC22A4—pituitary gland—Graves' disease	0.000256	0.0362	CbGeAlD
Imipramine—SLC22A4—adipose tissue—Graves' disease	0.000255	0.0361	CbGeAlD
Imipramine—HTR7—connective tissue—Graves' disease	0.00025	0.0354	CbGeAlD
Imipramine—DRD2—eye—Graves' disease	0.000245	0.0347	CbGeAlD
Imipramine—SLC22A1—adipose tissue—Graves' disease	0.000243	0.0344	CbGeAlD
Imipramine—SLC22A3—adipose tissue—Graves' disease	0.000232	0.0329	CbGeAlD
Imipramine—SLC22A4—thyroid gland—Graves' disease	0.000221	0.0312	CbGeAlD
Imipramine—CHRM3—adipose tissue—Graves' disease	0.000201	0.0285	CbGeAlD
Imipramine—SLC22A3—thyroid gland—Graves' disease	0.000201	0.0284	CbGeAlD
Imipramine—HRH1—eye—Graves' disease	0.000193	0.0274	CbGeAlD
Imipramine—HRH1—connective tissue—Graves' disease	0.000186	0.0264	CbGeAlD
Imipramine—ADRA1A—adipose tissue—Graves' disease	0.000185	0.0262	CbGeAlD
Imipramine—DRD2—pituitary gland—Graves' disease	0.000182	0.0258	CbGeAlD
Imipramine—KCNH2—pituitary gland—Graves' disease	0.000179	0.0254	CbGeAlD
Imipramine—CHRM3—thyroid gland—Graves' disease	0.000174	0.0247	CbGeAlD
Imipramine—HTR2A—eye—Graves' disease	0.000162	0.0229	CbGeAlD
Imipramine—HTR2A—connective tissue—Graves' disease	0.000156	0.0221	CbGeAlD
Imipramine—HRH1—adipose tissue—Graves' disease	0.000143	0.0203	CbGeAlD
Imipramine—CYP1A2—thyroid gland—Graves' disease	0.000132	0.0187	CbGeAlD
Imipramine—HTR2A—pituitary gland—Graves' disease	0.00012	0.017	CbGeAlD
Imipramine—CYP2E1—thyroid gland—Graves' disease	0.000119	0.0169	CbGeAlD
Imipramine—ABCB1—pituitary gland—Graves' disease	7.86e-05	0.0111	CbGeAlD
Imipramine—ABCB1—adipose tissue—Graves' disease	7.83e-05	0.0111	CbGeAlD
Imipramine—ABCB1—thyroid gland—Graves' disease	6.77e-05	0.0096	CbGeAlD
Imipramine—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	1.96e-05	0.00345	CbGpPWpGaD
Imipramine—HTR7—Circadian rythm related genes—FAS—Graves' disease	1.95e-05	0.00344	CbGpPWpGaD
Imipramine—SLC6A3—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.95e-05	0.00343	CbGpPWpGaD
Imipramine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.94e-05	0.00343	CbGpPWpGaD
Imipramine—CHRM5—GPCR ligand binding—TSHR—Graves' disease	1.9e-05	0.00334	CbGpPWpGaD
Imipramine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.79e-05	0.00316	CbGpPWpGaD
Imipramine—ADRA1D—GPCR ligand binding—TSHR—Graves' disease	1.78e-05	0.00314	CbGpPWpGaD
Imipramine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.78e-05	0.00314	CbGpPWpGaD
Imipramine—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.78e-05	0.00314	CbGpPWpGaD
Imipramine—SLC22A2—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.77e-05	0.00312	CbGpPWpGaD
Imipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.76e-05	0.00311	CbGpPWpGaD
Imipramine—HRH1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.76e-05	0.0031	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—HLA-B—Graves' disease	1.76e-05	0.0031	CbGpPWpGaD
Imipramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.75e-05	0.00309	CbGpPWpGaD
Imipramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.75e-05	0.00308	CbGpPWpGaD
Imipramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.73e-05	0.00305	CbGpPWpGaD
Imipramine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.73e-05	0.00304	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—FASLG—Graves' disease	1.72e-05	0.00303	CbGpPWpGaD
Imipramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.68e-05	0.00296	CbGpPWpGaD
Imipramine—HTR1A—G alpha (i) signalling events—CXCL10—Graves' disease	1.66e-05	0.00292	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—FAS—Graves' disease	1.66e-05	0.00292	CbGpPWpGaD
Imipramine—SLC22A1—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.65e-05	0.00291	CbGpPWpGaD
Imipramine—KCNH2—SIDS Susceptibility Pathways—IL1B—Graves' disease	1.65e-05	0.00291	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—IL2RA—Graves' disease	1.65e-05	0.00291	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—HLA-A—Graves' disease	1.63e-05	0.00287	CbGpPWpGaD
Imipramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.61e-05	0.00284	CbGpPWpGaD
Imipramine—HTR1A—GPCR ligand binding—TSHR—Graves' disease	1.55e-05	0.00274	CbGpPWpGaD
Imipramine—HTR2C—GPCR ligand binding—TSHR—Graves' disease	1.55e-05	0.00273	CbGpPWpGaD
Imipramine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.51e-05	0.00267	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	1.49e-05	0.00262	CbGpPWpGaD
Imipramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—Graves' disease	1.49e-05	0.00262	CbGpPWpGaD
Imipramine—ADRA1B—GPCR ligand binding—TSHR—Graves' disease	1.48e-05	0.00261	CbGpPWpGaD
Imipramine—DRD2—G alpha (i) signalling events—CXCL10—Graves' disease	1.46e-05	0.00257	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—GC—Graves' disease	1.42e-05	0.00251	CbGpPWpGaD
Imipramine—CHRM2—G alpha (i) signalling events—CXCL10—Graves' disease	1.41e-05	0.00248	CbGpPWpGaD
Imipramine—DRD2—GPCR ligand binding—TSHR—Graves' disease	1.37e-05	0.00241	CbGpPWpGaD
Imipramine—HTR6—GPCR ligand binding—CXCL10—Graves' disease	1.36e-05	0.00239	CbGpPWpGaD
Imipramine—HTR7—GPCR ligand binding—CXCL10—Graves' disease	1.36e-05	0.00239	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—GC—Graves' disease	1.35e-05	0.00237	CbGpPWpGaD
Imipramine—HTR2A—GPCR ligand binding—TSHR—Graves' disease	1.34e-05	0.00237	CbGpPWpGaD
Imipramine—HRH1—GPCR ligand binding—TSHR—Graves' disease	1.34e-05	0.00236	CbGpPWpGaD
Imipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	1.34e-05	0.00236	CbGpPWpGaD
Imipramine—CHRM1—GPCR ligand binding—TSHR—Graves' disease	1.34e-05	0.00235	CbGpPWpGaD
Imipramine—CHRM3—GPCR ligand binding—TSHR—Graves' disease	1.33e-05	0.00235	CbGpPWpGaD
Imipramine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.32e-05	0.00233	CbGpPWpGaD
Imipramine—CHRM2—GPCR ligand binding—TSHR—Graves' disease	1.32e-05	0.00232	CbGpPWpGaD
Imipramine—ADRA1A—GPCR ligand binding—TSHR—Graves' disease	1.32e-05	0.00232	CbGpPWpGaD
Imipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.31e-05	0.00231	CbGpPWpGaD
Imipramine—CHRM4—GPCR ligand binding—CXCL10—Graves' disease	1.28e-05	0.00226	CbGpPWpGaD
Imipramine—DRD2—Circadian rythm related genes—FAS—Graves' disease	1.27e-05	0.00224	CbGpPWpGaD
Imipramine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.26e-05	0.00221	CbGpPWpGaD
Imipramine—CHRM1—Circadian rythm related genes—FAS—Graves' disease	1.24e-05	0.00219	CbGpPWpGaD
Imipramine—CHRM5—GPCR ligand binding—CXCL10—Graves' disease	1.23e-05	0.00216	CbGpPWpGaD
Imipramine—KCNH2—SIDS Susceptibility Pathways—TNF—Graves' disease	1.2e-05	0.00211	CbGpPWpGaD
Imipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	1.19e-05	0.0021	CbGpPWpGaD
Imipramine—HTR6—GPCR downstream signaling—TSHR—Graves' disease	1.19e-05	0.00209	CbGpPWpGaD
Imipramine—HTR7—GPCR downstream signaling—TSHR—Graves' disease	1.19e-05	0.00209	CbGpPWpGaD
Imipramine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.16e-05	0.00204	CbGpPWpGaD
Imipramine—ADRA1D—GPCR ligand binding—CXCL10—Graves' disease	1.15e-05	0.00203	CbGpPWpGaD
Imipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.14e-05	0.00201	CbGpPWpGaD
Imipramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.14e-05	0.002	CbGpPWpGaD
Imipramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.13e-05	0.002	CbGpPWpGaD
Imipramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.13e-05	0.00199	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	1.12e-05	0.00198	CbGpPWpGaD
Imipramine—CHRM4—GPCR downstream signaling—TSHR—Graves' disease	1.12e-05	0.00197	CbGpPWpGaD
Imipramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.12e-05	0.00197	CbGpPWpGaD
Imipramine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	1.12e-05	0.00197	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—IFNG—Graves' disease	1.09e-05	0.00192	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—B3GNT2—Graves' disease	1.08e-05	0.0019	CbGpPWpGaD
Imipramine—SLC6A4—SIDS Susceptibility Pathways—TNF—Graves' disease	1.08e-05	0.0019	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—TSHR—Graves' disease	1.08e-05	0.0019	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—TSHR—Graves' disease	1.08e-05	0.0019	CbGpPWpGaD
Imipramine—CHRM5—GPCR downstream signaling—TSHR—Graves' disease	1.07e-05	0.00189	CbGpPWpGaD
Imipramine—HTR1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	1.04e-05	0.00183	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—B3GNT2—Graves' disease	1.02e-05	0.0018	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—TSHR—Graves' disease	1.02e-05	0.00179	CbGpPWpGaD
Imipramine—ADRA1D—GPCR downstream signaling—TSHR—Graves' disease	1.01e-05	0.00178	CbGpPWpGaD
Imipramine—HTR1A—GPCR ligand binding—CXCL10—Graves' disease	1e-05	0.00177	CbGpPWpGaD
Imipramine—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	1e-05	0.00176	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—TSHR—Graves' disease	9.74e-06	0.00172	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—IL1B—Graves' disease	9.7e-06	0.00171	CbGpPWpGaD
Imipramine—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	9.68e-06	0.00171	CbGpPWpGaD
Imipramine—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	9.57e-06	0.00169	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—TSHR—Graves' disease	9.16e-06	0.00161	CbGpPWpGaD
Imipramine—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	8.95e-06	0.00158	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—GC—Graves' disease	8.94e-06	0.00158	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—GC—Graves' disease	8.93e-06	0.00157	CbGpPWpGaD
Imipramine—DRD2—GPCR ligand binding—CXCL10—Graves' disease	8.82e-06	0.00155	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—TSHR—Graves' disease	8.79e-06	0.00155	CbGpPWpGaD
Imipramine—CHRM2—SIDS Susceptibility Pathways—IL1B—Graves' disease	8.79e-06	0.00155	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	8.75e-06	0.00154	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	8.74e-06	0.00154	CbGpPWpGaD
Imipramine—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	8.68e-06	0.00153	CbGpPWpGaD
Imipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	8.66e-06	0.00153	CbGpPWpGaD
Imipramine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	8.66e-06	0.00153	CbGpPWpGaD
Imipramine—HRH1—GPCR ligand binding—CXCL10—Graves' disease	8.66e-06	0.00153	CbGpPWpGaD
Imipramine—CHRM1—GPCR ligand binding—CXCL10—Graves' disease	8.63e-06	0.00152	CbGpPWpGaD
Imipramine—CHRM3—GPCR ligand binding—CXCL10—Graves' disease	8.61e-06	0.00152	CbGpPWpGaD
Imipramine—CHRM2—GPCR ligand binding—CXCL10—Graves' disease	8.52e-06	0.0015	CbGpPWpGaD
Imipramine—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	8.5e-06	0.0015	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	8.49e-06	0.0015	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	8.37e-06	0.00147	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—GC—Graves' disease	8.32e-06	0.00147	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	8.18e-06	0.00144	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—TSHR—Graves' disease	7.98e-06	0.00141	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—TSHR—Graves' disease	7.94e-06	0.0014	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—TSHR—Graves' disease	7.71e-06	0.00136	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—GC—Graves' disease	7.69e-06	0.00136	CbGpPWpGaD
Imipramine—HTR6—GPCR downstream signaling—CXCL10—Graves' disease	7.67e-06	0.00135	CbGpPWpGaD
Imipramine—HTR7—GPCR downstream signaling—CXCL10—Graves' disease	7.66e-06	0.00135	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	7.6e-06	0.00134	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	7.59e-06	0.00134	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—TSHR—Graves' disease	7.57e-06	0.00133	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—TSHR—Graves' disease	7.55e-06	0.00133	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—TSHR—Graves' disease	7.53e-06	0.00133	CbGpPWpGaD
Imipramine—HTR1A—SIDS Susceptibility Pathways—TNF—Graves' disease	7.52e-06	0.00132	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—TSHR—Graves' disease	7.45e-06	0.00131	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	7.43e-06	0.00131	CbGpPWpGaD
Imipramine—CHRM4—GPCR downstream signaling—CXCL10—Graves' disease	7.24e-06	0.00128	CbGpPWpGaD
Imipramine—ABCB1—Allograft Rejection—TNF—Graves' disease	7.04e-06	0.00124	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—TSHR—Graves' disease	7.01e-06	0.00123	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—CXCL10—Graves' disease	6.97e-06	0.00123	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—CXCL10—Graves' disease	6.96e-06	0.00123	CbGpPWpGaD
Imipramine—CHRM5—GPCR downstream signaling—CXCL10—Graves' disease	6.93e-06	0.00122	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—TSHR—Graves' disease	6.89e-06	0.00121	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—TSHR—Graves' disease	6.88e-06	0.00121	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—TSHR—Graves' disease	6.86e-06	0.00121	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—TSHR—Graves' disease	6.83e-06	0.0012	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—B3GNT2—Graves' disease	6.78e-06	0.00119	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—TSHR—Graves' disease	6.77e-06	0.00119	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—B3GNT2—Graves' disease	6.77e-06	0.00119	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	6.75e-06	0.00119	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—GC—Graves' disease	6.61e-06	0.00117	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—CXCL10—Graves' disease	6.57e-06	0.00116	CbGpPWpGaD
Imipramine—ADRA1D—GPCR downstream signaling—CXCL10—Graves' disease	6.51e-06	0.00115	CbGpPWpGaD
Imipramine—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	6.49e-06	0.00114	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—GC—Graves' disease	6.48e-06	0.00114	CbGpPWpGaD
Imipramine—CHRM2—SIDS Susceptibility Pathways—TNF—Graves' disease	6.38e-06	0.00112	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TSHR—Graves' disease	6.37e-06	0.00112	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TSHR—Graves' disease	6.36e-06	0.00112	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—B3GNT2—Graves' disease	6.31e-06	0.00111	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—CXCL10—Graves' disease	6.29e-06	0.00111	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TSHR—Graves' disease	6.01e-06	0.00106	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—CXCL10—Graves' disease	5.92e-06	0.00104	CbGpPWpGaD
Imipramine—HTR6—GPCR downstream signaling—IL2RA—Graves' disease	5.86e-06	0.00103	CbGpPWpGaD
Imipramine—HTR7—GPCR downstream signaling—IL2RA—Graves' disease	5.86e-06	0.00103	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—B3GNT2—Graves' disease	5.83e-06	0.00103	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TSHR—Graves' disease	5.75e-06	0.00101	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—CXCL10—Graves' disease	5.68e-06	0.001	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	5.65e-06	0.000996	CbGpPWpGaD
Imipramine—CHRM4—GPCR downstream signaling—IL2RA—Graves' disease	5.53e-06	0.000975	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TSHR—Graves' disease	5.41e-06	0.000953	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	5.41e-06	0.000953	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—IL2RA—Graves' disease	5.32e-06	0.000938	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—IL2RA—Graves' disease	5.32e-06	0.000937	CbGpPWpGaD
Imipramine—CHRM5—GPCR downstream signaling—IL2RA—Graves' disease	5.3e-06	0.000933	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—CXCL10—Graves' disease	5.16e-06	0.000909	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	5.13e-06	0.000904	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—IL2RA—Graves' disease	5.02e-06	0.000885	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—B3GNT2—Graves' disease	5.01e-06	0.000883	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—GC—Graves' disease	5e-06	0.000881	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	4.99e-06	0.000879	CbGpPWpGaD
Imipramine—ADRA1D—GPCR downstream signaling—IL2RA—Graves' disease	4.98e-06	0.000878	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	4.91e-06	0.000865	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—B3GNT2—Graves' disease	4.91e-06	0.000865	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	4.91e-06	0.000864	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—CXCL10—Graves' disease	4.89e-06	0.000863	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—CXCL10—Graves' disease	4.88e-06	0.00086	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—GC—Graves' disease	4.88e-06	0.00086	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—CXCL10—Graves' disease	4.86e-06	0.000857	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—CXCL10—Graves' disease	4.82e-06	0.000849	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—IL2RA—Graves' disease	4.81e-06	0.000848	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	4.8e-06	0.000846	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TSHR—Graves' disease	4.71e-06	0.000831	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TSHR—Graves' disease	4.69e-06	0.000826	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—GC—Graves' disease	4.6e-06	0.00081	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—CXCL10—Graves' disease	4.53e-06	0.000798	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—IL2RA—Graves' disease	4.52e-06	0.000797	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TSHR—Graves' disease	4.49e-06	0.000791	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	4.45e-06	0.000785	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—CXCL10—Graves' disease	4.44e-06	0.000783	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—CXCL10—Graves' disease	4.43e-06	0.000781	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—CXCL10—Graves' disease	4.42e-06	0.000778	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—CXCL10—Graves' disease	4.37e-06	0.000771	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	4.36e-06	0.000769	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—IL2RA—Graves' disease	4.34e-06	0.000765	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	4.32e-06	0.000761	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TSHR—Graves' disease	4.14e-06	0.000729	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	4.13e-06	0.000728	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—CXCL10—Graves' disease	4.11e-06	0.000725	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—CXCL10—Graves' disease	4.11e-06	0.000724	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TSHR—Graves' disease	4.07e-06	0.000718	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TSHR—Graves' disease	4.06e-06	0.000716	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TSHR—Graves' disease	4.05e-06	0.000714	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TSHR—Graves' disease	4.04e-06	0.000712	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TSHR—Graves' disease	4e-06	0.000705	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TSHR—Graves' disease	3.99e-06	0.000703	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—IL2RA—Graves' disease	3.94e-06	0.000695	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	3.92e-06	0.000691	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GC—Graves' disease	3.89e-06	0.000686	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—CXCL10—Graves' disease	3.88e-06	0.000684	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	3.81e-06	0.000672	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—B3GNT2—Graves' disease	3.79e-06	0.000668	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	3.75e-06	0.000661	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	3.75e-06	0.000661	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—IL2RA—Graves' disease	3.74e-06	0.000659	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—IL2RA—Graves' disease	3.73e-06	0.000657	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—CXCL10—Graves' disease	3.72e-06	0.000655	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—IL2RA—Graves' disease	3.72e-06	0.000655	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—B3GNT2—Graves' disease	3.7e-06	0.000652	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—IL2RA—Graves' disease	3.68e-06	0.000649	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	3.67e-06	0.000647	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CXCL10—Graves' disease	3.49e-06	0.000616	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—B3GNT2—Graves' disease	3.48e-06	0.000614	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	3.47e-06	0.000612	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—IL2RA—Graves' disease	3.46e-06	0.00061	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	3.4e-06	0.0006	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—IL2RA—Graves' disease	3.4e-06	0.000599	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—IL2RA—Graves' disease	3.39e-06	0.000597	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—IL2RA—Graves' disease	3.38e-06	0.000595	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—IL2RA—Graves' disease	3.34e-06	0.000589	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	3.33e-06	0.000588	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL2RA—Graves' disease	3.14e-06	0.000554	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL2RA—Graves' disease	3.14e-06	0.000554	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CXCL10—Graves' disease	3.05e-06	0.000537	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CXCL10—Graves' disease	3.03e-06	0.000534	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GC—Graves' disease	3.01e-06	0.00053	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL2RA—Graves' disease	2.97e-06	0.000523	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—B3GNT2—Graves' disease	2.95e-06	0.00052	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	2.9e-06	0.000511	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL2RA—Graves' disease	2.84e-06	0.000501	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CXCL10—Graves' disease	2.67e-06	0.000471	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL2RA—Graves' disease	2.67e-06	0.000471	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CXCL10—Graves' disease	2.63e-06	0.000464	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CXCL10—Graves' disease	2.63e-06	0.000463	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CXCL10—Graves' disease	2.62e-06	0.000461	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CXCL10—Graves' disease	2.61e-06	0.00046	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CXCL10—Graves' disease	2.58e-06	0.000455	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	2.58e-06	0.000454	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL2RA—Graves' disease	2.33e-06	0.00041	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL2RA—Graves' disease	2.32e-06	0.000408	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—B3GNT2—Graves' disease	2.28e-06	0.000401	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	2.22e-06	0.000391	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL2RA—Graves' disease	2.04e-06	0.00036	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL2RA—Graves' disease	2.01e-06	0.000354	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL2RA—Graves' disease	2.01e-06	0.000354	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL2RA—Graves' disease	2e-06	0.000353	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL2RA—Graves' disease	1.99e-06	0.000351	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL2RA—Graves' disease	1.97e-06	0.000348	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	1.97e-06	0.000347	CbGpPWpGaD
